You are here: Industry Insights > DS-1062

News List

AstraZeneca, Daiichi Sankyo Announce Collaboration for New Antibody Drug Conjugate americanpharmaceuticalreview
August 04, 2020
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential ...
Daiichi Sankyo, AstraZeneca Enter New $6B Global ADC Alliance contractpharma
August 03, 2020
To jointly develop and commercialize DS-1062, a TROP2 directed DXd antibody drug conjugate in Phase I for non-small cell lung cancer and breast cancer.
AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo pharmaceutical-technology
July 28, 2020
AstraZeneca has signed a new agreement to develop and commercialise Japanese company Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), DS-1062, globally for various tumour types.
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer pharmaceutical-business-review
July 06, 2020
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).